InspireMD Inc(NYSEMKT:NSPR) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $540.00K. Analysts estimated a revenue of $800.00K. Earnings per share were $-0.16. Analysts had estimated an EPS of $-0.17.
InspireMD Inc (NSPR) shares turned negative on Wednesdays trading session with the shares closing down -0.0115 points or -6.89% at a volume of 18,43,589. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.174. The peak price level was also seen at $0.174 while the days lowest was $0.1521. Finally the shares closed at $0.1555. The 52-week high of the shares is $2.495 while the 52-week low is $0.1504. According to the latest information available, the market cap of the company is $4.6 M.
Several Insider Transactions has been reported to the SEC. On Mar 23, 2016, Sol J Barer (director) purchased 847,458 shares at $0.59 per share price.Also, On Mar 23, 2016, Paul Stuka (director) purchased 127,119 shares at $0.59 per share price.On Mar 23, 2016, James J Loughlin (director) purchased 50,000 shares at $0.59 per share price, according to the Form-4 filing with the securities and exchange commission.
InspireMD Inc. is a medical device company. The Company is focused on the development and commercialization of its MicroNet stent platform technology for the treatment of complex coronary and vascular disease. The Company’s MicroNet a micron mesh sleeve is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s MGuard coronary products combining MicroNet and a bare-metal stent (MGuard Prime Embolic Protection Stent (EPS)) are marketed for use in patients with acute coronary syndromes notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Company’s second product CGuard carotid embolic prevention system (EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company is also developing a pipeline of other products and additional applications by leveraging its MicroNet technology.